Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:firstDescribedBy |
healthcare_professionals
|
| gptkbp:hasClient |
oprelvekin
|
| gptkbp:hasConflictWith |
hypersensitivity to oprelvekin
|
| gptkbp:hasFilm |
dizziness
fatigue headache nausea fever |
| gptkbp:hasFlavor |
24 months
|
| gptkbp:hasPerformedAt |
injection
|
| gptkbp:hasProductLine |
gptkb:OPKO_Health,_Inc.
|
| gptkbp:hasResidence |
store at 2 to 8 degrees Celsius
|
| https://www.w3.org/2000/01/rdf-schema#label |
OPKO 500
|
| gptkbp:isAssociatedWith |
improved quality of life
improved platelet counts reduced bleeding risk |
| gptkbp:isAttendedBy |
gptkb:FDA
hospital settings subcutaneous injection cancer patients outpatient settings |
| gptkbp:isAvailableIn |
vials
|
| gptkbp:isConsidered |
therapeutic agent
second-line treatment first-line treatment |
| gptkbp:isDiscussedIn |
medical literature
|
| gptkbp:isDocumentedIn |
clinical studies
|
| gptkbp:isEvaluatedBy |
patient outcomes
safety efficacy healthcare_professionals |
| gptkbp:isFundedBy |
gptkb:OPKO_Health,_Inc.
|
| gptkbp:isMarketedAs |
brand name
|
| gptkbp:isPartOf |
treatment protocols
chemotherapy-induced thrombocytopenia hematology treatment regimens oncology treatment regimens other thrombocytopenia treatments thrombocytopenia treatments OPKO_Health_product_line |
| gptkbp:isRecognizedFor |
children
pregnant women nursing mothers elderly patients with renal impairment |
| gptkbp:isRelatedTo |
cytokines
bone marrow platelet production |
| gptkbp:isSubjectTo |
clinical trials
regulatory review |
| gptkbp:isUsedFor |
treatment of thrombocytopenia
|
| gptkbp:isUsedIn |
oncology
hematology clinical settings |
| gptkbp:providesGuidelinesFor |
clinical practice guidelines for thrombocytopenia
|